Answers are grounded in this paper and cite their sources.
Sir, We agree with the suggestions of Gauthier and colleagues (Gauthier et al., 2018) for a more structured approach to therapy in Alzheimer’s disease. We also agree that there is substantial evidence towards beneficial effects of cholinesterase inhibitors for patients suffering from Alzheimer’s disease. This is why the Cholinergic System Working Group (CSWG) (Hampel et al., 2018a) concluded that ‘the weight of evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression’. We would like to expand the debate and take the arguments further. Evolving clinical and translational research evidence indicates that cholinesterase inhibitors and cholinergic receptor modulators may have a substantial biological, potentially disease-modifying effects in individuals with prodromal and Alzheimer’s disease dementia (Hampel et al., 2018a). We hypothesize that cholinergic compounds with high selectivity and affinity represent a promising therapeutic strategy to potentially impact relevant pathophysiological mechanisms and may delay disease progression when initiated at an even earlier preclinical stage. Studies in prodromal Alzheimer’s disease patients used neuroimaging markers as primary outcome measures. Positive trial results led to the notion that neuroprotective effects of cholinesterase inhibitors may have impacted the pathological disease progression. The Hippocampus Study, a double-blind randomized controlled trial of donepezil, demonstrated significant treatment effects in substantially reducing annual rate of atrophy of the hippocampus, regional cortical thickness and basal forebrain (Dubois et al., 2015; Cavedo et al., 2016, 2017). Studies using task-based functional MRI or molecular PET reported specific regional treatment effects of cholinergic drugs during prodromal and dementia stages of Alzheimer’s disease (Teipel et al., 2006; Bokde et al., 2016). Based on these promising new study findings we suggest reflecting novel trials and optimizations of study design investigating cholinesterase inhibitors. First, cognitive intact older adults at risk or asymptomatic individuals during preclinical stages of Alzheimer’s disease may be included in cholinesterase inhibitors trials, and could be stratified by sex and genomic profiles (Hampel et al., 2018d). Second, we suggest biomarker-guided monitoring of drug safety and efficacy (Aghourian et al., 2017) and surrogate outcome. Third, traditional pharmacodynamic and pharmacokinetic parameters of cholinesterase inhibitors should be integrated and analysed at the systems level (from the molecular to the organ level) through computational algorithms according to the emerging precision pharmacology protocols (currently in development). Precision pharmacology will be useful to identify target populations and to optimize dose-finding evaluations through biomarker-driven investigation of efficacy and toxicity across trial different phases (Hampel et al., 2018c). Finally, the generation of standardized multi-modal analysis platforms including big neuroimaging–(gen)omics data and taking advantage of progress in data science, such as integrated disease modelling (IDM), will present a substantial step forward to establish the true impact of mechanistic compounds related to aspects of Alzheimer’s disease pathophysiology, such as cholinesterase inhibitors (and future cholinergic receptor modulators) (Hampel et al., 2018b). Outcome could be demonstrated on the basis of brain–(gen)omic endophenotypes representing specific brain structural, functional and metabolic cholinergic system alterations associated with the individual genetic underpinning (Nho et al., 2013). Moreover, target population stratification through individualized neuroimaging–(gen)omic features will accelerate drug development using reliable predictive models of treatment response targeting both safety and efficacy outcomes (Hampel et al., 2018c). A comprehensive approach integrating the above mentioned requirements may provide a true exploration of putative disease-modifying effects of cholinesterase inhibitors according to standardized proof of pharmacology protocols: hitting the target, altering the pathophysiological mechanism, leading to a subsequent lasting clinical benefit (Cummings et al., 2018). In conclusion, the development of innovative clinical trial design, implementing multiple biomarkers for several contexts of use (O’Bryant et al., 2017) seems very timely to inform research and development programs not only for cholinesterase inhibitors but for all compounds in development for pathophysiological mechanisms related to Alzheimer’s disease other neurogenerative diseases. The development of such precision pharmacology programs will support the reevaluation of cholinesterase inhibitors or of compounds that have previously failed under the conventional ‘one-size fits all’ research and development paradigm and will pave the way for the transition of precision medicine to neuroscience and neurology, that will ensure the future clinician to treat the right patient, at the right time with the right biomarker-guided multi-target (combination) therapy, including cholinesterase inhibitors, tailored to the precise individual biological profile rather than to a largely unspecific clinical descriptive phenotype (classical clinical diagnosis) alone (Hampel et al., 2018b). Based on newly-established evidence it is time to give cholinesterase inhibitors, alone or in combination, a second chance to prove their true potential to benefit Alzheimer’s disease patients at different disease stages. Data sharing is not applicable to this article as no new data were created or analysed in this study. H.H. is supported by the AXA Research Fund, the “Fondation partenariale Sorbonne Université” and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. Ce travail a bénéficié d’une aide de l’Etat “Investissements d'avenir” ANR-10-IAIHU-06. The research leading to these results has received funding from the program “Investissements d'avenir” ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6). This manuscript benefited from the support of the Program “PHOENIX” led by the Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer (H.H., E.C. and A.V.). H.H. serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia; he received lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE-Healthcare and Oryzon Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. H.H. is co-inventor in the following patents as a scientific expert and has received no royalties: In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388. In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784. Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300. In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463. In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286. In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822. In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553. CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797. In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966. Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921. A.V. and E.C. have nothing of relevance to declare.
No takes yet. Share an insight, caveat, or question.
Hampel et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: